More gloomy news from Finch Therapeutics, as the microbiome company announced it would scrap the Phase III PRISM4 trial of its recurrent C. difficile infection 25 January 2023
Nkarta, a US biopharma developing engineered natural killer (NK) cell therapies to treat cancer, has announced the appointment of a chief medical officer (CMO). 11 January 2023
CAR-T therapy company Allogene Therapeutics has swiftly named its replacement for executive vice president of research and development Rafael Amado, who has res 3 January 2023
French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecul 14 December 2022
The retiring Paul Perreault is to be replaced by another Paul as chief executive and managing director of Australian biotech CSL Limited. 13 December 2022
Anjarium Biosciences, a Swiss biotech focused on creating and delivering a new class of non-viral gene therapies, has announced the appointment of Otmane Boussi 8 December 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.